Product Detail
rac-Rasagiline-13C3 N-Carbamoyl β-D-Glucuronide
Stable Isotopes
Stock Status: Enquire
Live
For Research & Analytical Purposes. Not for Personal use.
Category
Stable Isotopes
API Family
--
Storage
Refer MSDS for complete information.
Hazard Information
Refer MSDS for complete information.
rac-Rasagiline-13C3 N-Carbamoyl β-D-Glucuronide Product Information
rac-Rasagiline-13C3 N-Carbamoyl β-D-Glucuronide is listed under Stable Isotopes. It is associated with and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-97191.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight, stock enquiry details and supporting documentation.
Technical Data
Product Name
rac-Rasagiline-13C3 N-Carbamoyl β-D-Glucuronide
CAS No.
-
CAT No.
CS-T-97191
Molecular Formula
C16¹³C3H21NO8
Molecular Weight
394.35
Category
Storage Condition
Refer MSDS for complete information.
IUPAC Name
rac-Rasagiline-13C3 N-Carbamoyl ß-D-Glucuronide
Hazard Compound
Refer MSDS for complete information.
Description
Overview
"rac-Rasagiline-13C3 N-Carbamoyl ß-D-Glucuronide is the labeled racemic analogue of Rasagiline N-Carbamoyl ß-D-Glucuronide (R126025), a metabolite of Rasagiline (R126030), a selective and irreversible propargylamine inhibitor of monoamine oxidase which has been used to increase the availability of dopamine at striatal receptors as a method to treat Parkinson’s disease."
Synonyms
"(2S,3S,4S,5R,6S)-6-(((rac-2,3-Dihydro-1H-inden-1-yl)(prop-2-yn-1-yl-13C3)carbamoyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic Acid"
Application Notes
"rac-Rasagiline-13C3 N-Carbamoyl ß-D-Glucuronide is the labeled racemic analogue of Rasagiline N-Carbamoyl ß-D-Glucuronide (R126025), a metabolite of Rasagiline (R126030), a selective and irreversible propargylamine inhibitor of monoamine oxidase which has been used to increase the availability of dopamine at striatal receptors as a method to treat Parkinson’s disease."
References
"Youdim, M.B.H., et al.: Br. J. Pharmacol., 132, 500 (2001); Finberg, J.P., Rambam Maimonides Med. J., 1 (2010)"
